3rd International AIDS Society Conference on HIV Pathogenesis and Treatment Rio de Janeiro - July 24 - 27, 2005

EVALUATION OF ESAT-6 & CFP-10 – SPECIFIC T LYMPHOCYTES IN CO-INFECTED WITH HIV-1 AND M. TUBERCULOSIS BULGARIAN PATIENTS DURING SPECIFIC ANTI-TUBERCULOSIS THERAPY

IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd: Abstract No. TuPe7.1C02

Markova R.¹, Drenska R.¹, Terzieva V.¹, Todorova Y.¹, Elenkov I.², Yankova M.², Yankova M.², Kostov K.², Stefanova D.^3
1National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria, ²Infectious Diseases Hospital 'Prof. I. Kirov', Sofia, Bulgaria, ³Hospital for Lung Diseases and Tuberculosis 'St. Sofia', Sofia, Bulgaria

INTRODUCTION: Monitoring the efficacy of anti-tuberculosis therapy is crucial both for the individual patient and for better control of the spread of Tuberculosis. Certain highly immunogenic secreted antigens of M. tuberculosis such as ESAT-6 and CFP-10, offer hope for more specific diagnosis of M. tuberculosis infection. Our aim was to study the dynamics of ESAT-6 and CFP-10 – specific IFN-γ producing T cells during specific anti-tuberculosis therapy in co-infected with HIV-1 and M. tuberculosis patients.

METHODS: 10 HIV/TB patients were studied at the time of diagnosis and 3 months after they started therapy. Eight of them were with microbiologically confirmed tuberculosis. An in vitro enzyme-linked immunospot (T SPOT-TB, Oxford Immunotec) assay and an ELISA (QuantiFERON-TB Gold, Cellestis, Australia) that detect T cell-mediated IFN-γ responses to ESAT-6 and CFP-10 proteins were used.

RESULTS: All patients had positive results at diagnosis; 3 months later the responses to ESAT-6 and CFP-10 were still detectable in two patients with microbiological isolation and/or absence of clinical improvement after treatment.

CONCLUSIONS: On the basis of our data obtained even from a small number of patients we conclude that the in vitro ELISPOT and ELISA assays are useful tools in monitoring the efficacy of antituberculosis therapy especially in HIV/MTB patients.

Acknowledgements: We are grateful to Ajit Lalvani, Chris Granger (Oxford Immunotec) and Jim Rothel (Cellestis) for their scientific collaboration.

Download PDF of this abstract.

050724
Clinical | TuPe7.1C02 | Roumiana Markova
Tuberculosis

Copyright © 2005 - International AIDS Society (IAS). All information and content relating to the abstracts from the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.

AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.